Little-Known Cholesterol Test Now Recommended to Prevent Heart Disease

For decades, the standard cholesterol panel has been a cornerstone of preventive medicine — LDL, HDL, triglycerides, total cholesterol. Millions of Americans get these numbers checked annually, adjust their diets, and in many cases start statin therapy based on the results. But there is a critical gap in that familiar blood test, and on March 13, 2026, the nation's leading cardiology organizations formally acknowledged it.

The American Heart Association and the American College of Cardiology, joined by nine other major medical associations, released their most comprehensive update to cholesterol management guidelines in nearly a decade [1][2]. Among the most consequential recommendations: every adult in America should receive a one-time blood test for a cholesterol particle most people have never heard of — lipoprotein(a), commonly written as Lp(a) and pronounced "L-P-little-a."

The announcement marks a turning point in cardiovascular prevention. For years, cardiologists and lipid specialists have known that Lp(a) is a powerful, independent risk factor for heart attack, stroke, and aortic valve disease. But because no approved drug specifically targets it, testing has remained a niche practice, ordered for fewer than 1% of patients [3]. That is about to change.

What Is Lipoprotein(a) — And Why Has It Been Overlooked?

Lipoprotein(a) is a particle in the blood that closely resembles LDL cholesterol — the so-called "bad cholesterol" — but with a critical distinction. Attached to its surface is a protein called apolipoprotein(a), which gives the particle unique properties that promote blood clotting and arterial inflammation [4][5].

Unlike LDL, which can be managed through diet, exercise, and medication, Lp(a) levels are almost entirely determined by genetics. A person's Lp(a) level is set at birth by variations in the LPA gene and remains remarkably stable throughout life. It is not significantly affected by diet, exercise, or conventional statin therapy [4][6].

This genetic permanence is precisely what makes universal testing practical — and why a single test, ideally performed early in adulthood, is sufficient for a lifetime of risk stratification. But it is also what has kept Lp(a) on the margins of clinical practice. Without a targeted therapy to lower it, many physicians saw little point in measuring something they could not directly treat.

"There's been a longstanding frustration in cardiology," said Dr. Steven Nissen, a leading cardiologist at the Cleveland Clinic. "We've known Lp(a) is dangerous for over 30 years, but we didn't have a specific treatment. That calculus is now changing" [7].

The Scale of the Problem

The numbers are staggering. Approximately one in five people worldwide — and an estimated 64 million Americans — carry elevated Lp(a) levels above 50 mg/dL (or 125 nmol/L), the threshold the new guidelines identify as high risk [4][5][8]. For these individuals, the risk of a heart attack or stroke may be two to three times higher than for those with normal levels [5].

The disparities are stark across racial and ethnic groups. Research published in JACC: Advances found that 52% of Black participants had Lp(a) levels at or above the high-risk threshold, compared to roughly 33% of the general population [9]. Black populations of sub-Saharan descent carry median Lp(a) levels more than 2.5 times higher than the overall population, followed by South Asian, white, Hispanic, and East Asian groups [9][10].

These disparities carry profound implications. Cardiovascular disease already disproportionately affects Black Americans and South Asian populations. If elevated Lp(a) is a significant, genetically determined contributor to that disparity — and growing evidence suggests it is — then the failure to routinely test for it has represented a blind spot in health equity.

Source: World Bank / WHO

Data as of Feb 24, 2026CSV

Inside the New Guidelines

The 2026 ACC/AHA Guideline on the Management of Dyslipidemia is a sprawling document that reshapes cardiovascular prevention across multiple dimensions [1][2]. Its key provisions include:

Universal Lp(a) Testing: All adults should have their Lp(a) measured at least once in their lifetime, ideally early in adulthood. Individuals with levels at or above 125 nmol/L (50 mg/dL) are classified as high risk and should receive intensified management of all other cardiovascular risk factors [1][2].

Lowered Statin Age Threshold: For the first time, the guidelines recommend considering statin therapy for patients as young as 30, down from the previous threshold of 40. This applies particularly to individuals with LDL cholesterol at or above 160 mg/dL, heterozygous familial hypercholesterolemia, a strong family history of premature heart disease, or a high 30-year risk score [2][3].

A New Risk Calculator: The outdated Pooled Cohort Equations, which were found to overestimate 10-year heart attack and stroke risk by 40% to 50%, are replaced by the PREVENT-ASCVD calculator. The new tool evaluates adults ages 30 to 79, incorporates kidney function and BMI alongside traditional risk factors, and calculates both 10-year and 30-year risk [1][2].

More Aggressive LDL Targets: The guidelines set tiered LDL goals: below 100 mg/dL for borderline and intermediate risk patients, below 70 mg/dL for high-risk patients, and below 55 mg/dL for patients with existing atherosclerotic disease — the most aggressive targets ever set in U.S. guidelines [1][2].

Childhood Screening: Cholesterol screening is now recommended for all children between ages 9 and 11 [2].

"Lower LDL for longer results in greater protection against future heart attack and stroke risk," said Dr. Roger Blumenthal, chair of the guideline writing committee and a professor at Johns Hopkins Medicine [2].

The Paradigm Shift: Lifetime Risk Over Snapshots

Perhaps the most philosophically significant change in the new guidelines is the emphasis on cumulative, lifetime exposure to elevated cholesterol rather than point-in-time risk assessments.

Previous guidelines focused heavily on 10-year risk — the probability of a heart attack or stroke within the next decade. This approach tended to defer treatment for younger patients, even those with significantly elevated cholesterol, because their short-term risk appeared low simply by virtue of their age.

The new framework recognizes what cardiologists increasingly call "the cholesterol-years hypothesis": that the total burden of cholesterol exposure over a lifetime determines arterial damage, much like pack-years of smoking determine lung disease risk [3][11].

"A person's lifetime risk is what counts," Dr. Nissen told NPR. "These new guidelines will result in more people being treated earlier" [3].

Dr. Gregg Fonarow, a cardiologist at UCLA, called the shift "deeply important." He noted that prevention neglect — the tendency to delay treatment until risk becomes imminent — has been "deeply concerning" in clinical practice [11].

The Coming Wave of Lp(a) Drugs

The timing of the new testing recommendation is not coincidental. After decades without a targeted therapy, a wave of drugs designed specifically to lower Lp(a) is advancing through clinical trials, with the first approvals potentially arriving as soon as late 2026 or 2027 [7][12][13].

Pelacarsen (Ionis/Novartis): An antisense oligonucleotide (ASO) that inhibits production of apolipoprotein(a) in the liver. Phase 2 data showed approximately 80% reduction in Lp(a) levels. The phase 3 Lp(a)HORIZON trial, enrolling 8,323 patients with established cardiovascular disease and elevated Lp(a), has completed enrollment and top-line results are expected in the first half of 2026, with regulatory submissions anticipated in the second half of 2026 [12][13].

Olpasiran (Amgen): A small interfering RNA (siRNA) administered quarterly by injection. Phase 2 results demonstrated Lp(a) reductions exceeding 90%. The phase 3 OCEAN(a) trial, with over 7,200 patients enrolled, is expected to report results by December 2026 [12][13].

Zerlasiran (Silence Therapeutics): Another siRNA therapy that showed more than 80% Lp(a) reduction in a Cleveland Clinic-led phase 2 trial, with minimal side effects [7].

At least five investigational agents are in various stages of clinical testing, spanning three siRNA molecules and one ASO, all delivered by subcutaneous injection [12].

If the phase 3 outcomes trials demonstrate that lowering Lp(a) reduces heart attacks and strokes — not just the biomarker level — it would validate the therapeutic hypothesis that has driven this research for decades and could open a multibillion-dollar pharmaceutical market.

What Patients Should Know

For the estimated one in five adults who will discover they have elevated Lp(a), the immediate clinical implications are nuanced. Currently, there are no FDA-approved medications that specifically lower Lp(a). Lipoprotein apheresis, a dialysis-like procedure that physically filters lipoproteins from the blood, is the only FDA-approved treatment but is impractical for widespread use [12].

However, knowing one's Lp(a) status is far from meaningless even without a targeted drug. The new guidelines recommend that patients with elevated Lp(a) receive more aggressive management of every other modifiable risk factor — LDL cholesterol, blood pressure, blood sugar, weight, smoking cessation, and physical activity [1][2][4].

An elevated Lp(a) level may also tip the scales toward earlier or more intensive statin therapy, the addition of non-statin medications like ezetimibe or PCSK9 inhibitors, or the pursuit of coronary artery calcium scanning to better quantify existing arterial damage [1][2].

The National Lipid Association now recommends stratifying patients into three Lp(a) risk categories: low risk (below 75 nmol/L or 30 mg/dL), intermediate risk (75 to 125 nmol/L or 30 to 50 mg/dL), and high risk (at or above 125 nmol/L or 50 mg/dL) [8].

Critically, the test is a simple blood draw, widely available, and typically covered by insurance when ordered as part of cardiovascular risk assessment. Because Lp(a) is genetically stable, a single test in early adulthood provides actionable information for a lifetime [3][4].

Source: GDELT Project

Data as of Mar 14, 2026CSV

Questions and Concerns

Not everyone views the expanded guidelines without reservation. Some physicians and health policy experts have raised concerns about the potential for over-medicalization — placing millions of otherwise healthy young adults on lifetime statin therapy based on risk projections that span decades [11].

The question of statin side effects, including muscle pain and a small increased risk of diabetes, remains relevant when considering treatment for patients in their 30s who may face 40 or 50 years of medication use. The guidelines acknowledge these concerns but point to the extensive evidence base demonstrating statins' cardiovascular benefits and their generally favorable safety profile [2][11].

There are also practical challenges. Despite the guideline's recommendation, many primary care physicians remain unfamiliar with Lp(a) testing, and the test is not yet part of standard lipid panels ordered through electronic health record systems. Translating a guideline recommendation into routine clinical practice typically takes years, and physician education, lab workflow changes, and insurance coverage policies will all need to evolve [3][8].

The racial disparities in Lp(a) levels also raise complex questions about risk thresholds. Some researchers have questioned whether a single universal cutpoint of 50 mg/dL is appropriate across all populations, given that the 90th percentile threshold differs significantly between racial groups — 168 nmol/L for white individuals versus 212 nmol/L for Black individuals [9][10].

The Bigger Picture: 80% of Heart Disease Is Preventable

The new guidelines arrive against the backdrop of a sobering reality: cardiovascular disease remains the leading cause of death both in the United States and globally, despite being largely preventable [2]. Approximately one in four U.S. adults has elevated LDL cholesterol, yet the disease continues to claim nearly 700,000 American lives annually.

The ACC/AHA estimates that more than 80% of cardiovascular disease is preventable through lifestyle modifications and appropriate medical therapy [2]. The gap between that theoretical ceiling and the current state of prevention represents millions of preventable deaths.

By adding Lp(a) to the screening toolkit, lowering the age of intervention, and replacing an inaccurate risk calculator with a more precise one, the 2026 guidelines represent the most ambitious attempt yet to close that gap. Whether the healthcare system can implement these recommendations at scale — and whether patients will act on the information — remains the open question.

For the millions of Americans walking around with a hidden genetic risk factor they have never been told about, the answer to that question may be a matter of life and death.